It occurs almost two-fold higher in less developed countries compared with more-developed countries.1For individuals with uterine cervical malignancy, radiation therapy (RT) is an important treatment modality in a variety of clinical situations. COX-2, and six out of the eight individuals experienced a V2R greater than 0.5 (p=0.2222). == Summary == The poor mid-RT tumor response was associated with Velneperit the coexpression of COX-2 and EGFR. Keywords:Cervical malignancy, Radiotherapy, Volume response, Cyclooxygenase-2, Epidermal growth element receptor == Intro == Uterine cervical malignancy is the second most common female malignancy in the world. It occurs almost two-fold higher in less developed countries compared with more-developed countries.1For individuals with uterine cervical malignancy, radiation therapy (RT) is an important treatment modality in a variety of clinical situations. Especially in early cervical malignancy individuals, surgery treatment and RT are equal in terms of medical end result, and the treatment choice depends on the patient’s age, co-morbidities, etc. On the other hand, in locally advanced cervical malignancy individuals, concurrent chemoradiotherapy represents the standard treatment, RT only becoming reserved for unique conditions.2-5 In addition to FIGO stage, pelvic or para-aortic lymph node status, initial tumor size, and post-RT tumor size are well-established prognostic factors and predictors of outcome after RT in patients with cervical cancer.6-8Some investigators have suggested the tumor volume response, assessed at 4-5 weeks after initiation of RT, is definitely associated with local disease Velneperit control and disease free survival.9,10Recently, several studies have reported that specific biological markers, such as cyclooxygenase (COX)-2, epidermal growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF) are significantly correlated with tumor control, survival after RT with or without chemotherapy.11-18 The goals of this prospective study were 1) to determine the factors associated with the tumor volume response Velneperit to RT with or without chemotherapy and 2) to determine the relationship between the tumor volume response and alteration of the expression of the biological markers during RT with or without chemotherapy. == MATERIALS AND METHODS == == 1. Individuals == Twenty consecutive individuals with squamous cell carcinoma of the uterine cervix who received definitive RT, with or without chemotherapy, at Samsung Medical Center between March 2005 and November 2006 were evaluated (Table 1). When pelvic lymph nodes exceeded 1.5 cm in diameter and/or Rabbit polyclonal to Ataxin7 there was significant F18-fluorodeoxyglucose uptake by positron emission tomography (PET), the lymph node was considered positive for cancer involvement. Pre-treatment PET was performed in 12 individuals. Among them, seven individuals had significant irregular uptake in pelvic lymph nodes. The institutional review table approved this study and all individuals voluntarily participated with this study by signing the knowledgeable consent. == Table 1. == Patient characteristics FIGO: International Federation of Gynecology and Obstetrics, ECOG: Eastern Cooperative Oncology Group. == 2. Treatment == All individuals received a combination of external beam radiotherapy (EBRT) and high-dose-rate (HDR) intracavitary irradiation (ICR) by a remote after loading system with Ir-192. EBRT was delivered to the whole pelvis with 15-MV photon beams at a daily dose of 1 1.8 Gy, five times per week to a total dose of 50.4 Gy. The individuals were irradiated having a 4-field package technique in order to spare the small bowel anterior to the iliac nodes. Extended field irradiation including the para-aortic area, with a total dose of 45 Gy, was adminstered for just one affected individual with positive common iliac lymph nodes. HDR ICR was initiated after Velneperit an EBRT dosage of 41.4 Gy to 45 Gy with midline blocking. ICR was delivered twice a complete week in 6 fractions using a fractional dosage of 4 Gy in stage A. The median general treatment period was 53 times (range, 46 to 61 times). Three sufferers with FIGO stage IB or IIA disease who acquired small tumors significantly less than 3 cm didn’t obtain concurrent chemotherapy. The rest of the seventeen sufferers received concurrent chemoradiotherapy. Eleven sufferers received six cycles.